Literature DB >> 2964097

Emergency use of nebulised bronchodilator drugs in British hospitals.

B R O'Driscoll1, G M Cochrane.   

Abstract

A telephone survey was conducted to determine the emergency use of nebulised bronchodilator drugs by the registrar or senior house officer on duty for medical admissions at 67 British hospitals. All used a nebulised beta agonist (usually 5 mg salbutamol) as first line treatment for severe acute asthma or reversible obstructive lung disease. Twenty three doctors used ipratropium bromide occasionally and 38 used it frequently, usually mixing ipratropium and a beta agonist in the nebuliser chamber. Only five doctors routinely specified whether the nebuliser should be driven by air or by oxygen. In the case of a hypercapnic patient with chronic bronchitis, 11 respondents would not specify which gas should be used and a further 14 would use oxygen, a potentially dangerous practice. In the case of a hypoxic asthmatic patient, 22 doctors would not prescribe oxygen as the driving gas. The driving gas flow rate was almost invariably determined by nursing staff. Intravenous aminophylline was used by all 67 respondents (52 of them frequent users) but only 24 used intravenous beta agonists (five of them frequent users). It is concluded that nebulised bronchodilator drugs are the most commonly used treatment for acute asthma and reversible obstructive lung disease in hospital, but further instruction in their use is required for the staff who use them most frequently.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2964097      PMCID: PMC460804          DOI: 10.1136/thx.42.7.491

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma.

Authors:  R Beck; C Robertson; M Galdès-Sebaldt; H Levison
Journal:  J Pediatr       Date:  1985-10       Impact factor: 4.406

2.  A place for ipratropium bromide in the treatment of severe acute asthma.

Authors:  M J Ward; J T Macfarlane; D Davies
Journal:  Br J Dis Chest       Date:  1985-10

3.  Dosage and delivery of nebulised beta agonists in hospital.

Authors:  J N Stainforth; R A Lewis; A E Tattersfield
Journal:  Thorax       Date:  1983-10       Impact factor: 9.139

4.  Role of the parasympathetic system in airway obstruction due to emphysema.

Authors:  N J Gross; M S Skorodin
Journal:  N Engl J Med       Date:  1984-08-16       Impact factor: 91.245

5.  Audit of nebuliser use.

Authors:  P E Williams; S A Renowden; M J Ward
Journal:  Postgrad Med J       Date:  1985-12       Impact factor: 2.401

6.  Nebulized ipratropium bromide in the treatment of acute asthma.

Authors:  D H Bryant
Journal:  Chest       Date:  1985-07       Impact factor: 9.410

7.  Oxygen as a driving gas for nebulisers: safe or dangerous?

Authors:  K A Gunawardena; B Patel; I A Campbell; J B MacDonald; A P Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

8.  Bronchodilator responses to nebulised ipratropium and salbutamol singly and in combination in chronic bronchitis.

Authors:  C S Chan; I G Brown; C A Kelly; A G Dent; P V Zimmerman
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

  8 in total
  5 in total

1.  Treatment for acute asthma in the ambulance.

Authors:  C G Wathen; G K Crompton; D Carrington; J Hollingworth
Journal:  Br J Gen Pract       Date:  1990-09       Impact factor: 5.386

2.  Nebulizer therapy. Guidelines. British Thoracic Society Nebulizer Project Group.

Authors: 
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  Nebulisers for chronic obstructive pulmonary disease.

Authors:  B R O'Driscoll
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

4.  Intravenous beta agonist in severe acute asthma.

Authors: 
Journal:  BMJ       Date:  1988-09-24

5.  Intravenous beta agonist in severe acute asthma.

Authors:  B Cheong; S R Reynolds; G Rajan; M J Ward
Journal:  BMJ       Date:  1988-08-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.